Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
Subscribe To Our Newsletter & Stay Updated
